197 related articles for article (PubMed ID: 32951523)
1. Hypertension and QT interval prolongation associated with targeted systemic cancer therapies.
Fahey OG; Piccolo JK; Bergsbaken JJ; N Dow-Hillgartner E
J Oncol Pharm Pract; 2020 Dec; 26(8):1987-1996. PubMed ID: 32951523
[TBL] [Abstract][Full Text] [Related]
2. QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics.
Chandrasekhar S; Fradley MG
Curr Treat Options Oncol; 2019 May; 20(7):55. PubMed ID: 31129799
[TBL] [Abstract][Full Text] [Related]
3. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
Porta-Sánchez A; Gilbert C; Spears D; Amir E; Chan J; Nanthakumar K; Thavendiranathan P
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29217664
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).
Shah RR; Morganroth J; Shah DR
Drug Saf; 2013 May; 36(5):295-316. PubMed ID: 23620167
[TBL] [Abstract][Full Text] [Related]
5. Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.
Cuni R; Parrini I; Asteggiano R; Conte MR
Clin Drug Investig; 2017 Feb; 37(2):121-134. PubMed ID: 27638052
[TBL] [Abstract][Full Text] [Related]
6. Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs.
Pezo RC; Yan AT; Earle C; Chan KK
Heart; 2019 Nov; 105(21):1649-1655. PubMed ID: 31129611
[TBL] [Abstract][Full Text] [Related]
7. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.
Coppola C; Rienzo A; Piscopo G; Barbieri A; Arra C; Maurea N
Cancer Treat Rev; 2018 Feb; 63():135-143. PubMed ID: 29304463
[TBL] [Abstract][Full Text] [Related]
8. Approach to initiating QT-prolonging oncology drugs in the ambulatory setting.
de Lemos ML; Kung C; Kletas V; Badry N; Kang I
J Oncol Pharm Pract; 2019 Jan; 25(1):198-204. PubMed ID: 29298624
[TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
Strevel EL; Ing DJ; Siu LL
J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM
Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560
[TBL] [Abstract][Full Text] [Related]
11. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.
Khan Q; Ismail M; Khan S
BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
13. Protease inhibitor-associated QT interval prolongation.
Hunt K; Hughes CA; Hills-Nieminen C
Ann Pharmacother; 2011 Dec; 45(12):1544-50. PubMed ID: 22128044
[TBL] [Abstract][Full Text] [Related]
14. Sibutramine-associated QT interval prolongation and cardiac arrest.
Ernest D; Gershenzon A; Corallo CE; Nagappan R
Ann Pharmacother; 2008 Oct; 42(10):1514-7. PubMed ID: 18728104
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity of molecular-targeted drug therapy.
Le DL; Cao H; Yang LX
Anticancer Res; 2014 Jul; 34(7):3243-9. PubMed ID: 24982327
[TBL] [Abstract][Full Text] [Related]
16. Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers.
Escalante CP; Lu M; Marten CA
Curr Hypertens Rev; 2016; 12(2):112-20. PubMed ID: 26931476
[TBL] [Abstract][Full Text] [Related]
17. [Long QT Syndrome Induced by Antidepressants].
Suzuki Y
Seishin Shinkeigaku Zasshi; 2016; 118(3):147-151. PubMed ID: 30620510
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of QT prolongation associated with tamoxifen: A review of the literature.
Fung K; Imeson J; Cusano F
J Oncol Pharm Pract; 2018 Oct; 24(7):525-530. PubMed ID: 28728494
[TBL] [Abstract][Full Text] [Related]
19. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance and management of drug-related QT interval prolongation.
Crouch MA; Limon L; Cassano AT
Pharmacotherapy; 2003 Jul; 23(7):881-908. PubMed ID: 12885102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
